Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1075
- Registration Number
- NCT05629585
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05628038
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 220
- Registration Number
- NCT05625412
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
🇺🇸Local Institution - 0019, Los Angeles, California, United States
🇦🇷Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
- Conditions
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 312
- Registration Number
- NCT05610163
- Locations
- 🇺🇸
Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
🇺🇸Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05608785
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 226
- Registration Number
- NCT05609370
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
🇨🇳Nanyang Central Hospital, Nanyang, Henan, China
Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05585814
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Menoufia University
- Target Recruit Count
- 40
- Registration Number
- NCT05566743
- Locations
- 🇪🇬
Nahla Atef Shabaan, Cairo, Egypt
🇪🇬Egypt, Cairo, Egypt
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E）
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 34
- Registration Number
- NCT05555888
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.